Open access peer-reviewed chapter

Tissue Factor Pathway Inhibitor-2 Inhibits the Growth and Invasion of Hepatocellular Carcinoma Cells and is Inactivated in Human Hepatocellular Carcinoma

By Yong Xu, Xiaolin Qin, Jinjing Zhou, Zhiguang Tu, Xiao Bi, Wuxian Li, Xiaoqing Fan and Yi Zhang

Submitted: February 17th 2011Reviewed: August 19th 2011Published: February 10th 2012

DOI: 10.5772/27307

Downloaded: 1185

© 2012 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Yong Xu, Xiaolin Qin, Jinjing Zhou, Zhiguang Tu, Xiao Bi, Wuxian Li, Xiaoqing Fan and Yi Zhang (February 10th 2012). Tissue Factor Pathway Inhibitor-2 Inhibits the Growth and Invasion of Hepatocellular Carcinoma Cells and is Inactivated in Human Hepatocellular Carcinoma, Hepatocellular Carcinoma - Basic Research, Wan-Yee Lau, IntechOpen, DOI: 10.5772/27307. Available from:

chapter statistics

1185total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Proteoglycans in Chronic Liver Disease and Hepatocellular Carcinoma: An Update

By Péter Tátrai and Ilona Kovalszky

Related Book

First chapter

Hepatocellular Carcinoma: Epidemiology and Etiology

By Davide Degli Esposti, Morando Soffritti, Antoinette Lemoine, Eva Tibaldi and Marco Manservigi

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More about us